Compare Infosys Limited (INFY) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Altria Group Inc — how do they compare? Infosys Limited trades at $10.71 (market cap $41.69B), while Altria Group Inc trades at $71.02 (market cap $115.85B). The key difference: Altria Group Inc is far larger — about 2.8× Infosys Limited's market cap, and Altria Group Inc pays the higher dividend (6.4%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Altria Group Inc for 154 Days on average.
| INFY | MO | |
|---|---|---|
Market Cap | $41.69B | $115.85B |
Volume | 28,397,442 | 6,934,962 |
Sector | Technology | Consumer Staples |
52-Week High | $20.22 | $74.92 |
52-Week Low | $10.49 | $54.72 |
Typical Hold Time | 27 Days | 154 Days |
Enterprise Value | $39.44B | $138.06B |
Dividend Yield | 4.96% | 6.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.55, showing no change recently. The stock is in a bearish technical trend, with moving averages signaling sell pressure, while oscillators are neutral. Fundamentally, the company reported $19.28B in revenue for 2025 with a net income margin of 16.37%, and valuation ratios like a P/E of 13.02 suggest relative affordability. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation. Earnings history is mixed, with a beat in Q1 2026 but a miss in Q2 2026.
The outlook for INFY is cautious, with analyst consensus at a $11.48 price target and a 'Hold' bias (55% of ratings). Opportunities include strong profitability metrics like a 32.12% ROE and AI-driven growth initiatives, but risks involve bearish technical signals, potential earnings volatility, and competitive pressures in IT services. Net cash flow turned negative in 2026, indicating financial strain, which could limit upside near-term.
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
